It contributes around 80% of outflow in a normal eye1
Episcleral venous pressure physiologically creates a barrier that may avoid hypotony
75% of surgeons want to restore natural outflow via the conventional outflow pathway first2
With its unique implant-free approach, the OMNI Surgical System lets you access Schlemm’s canal with the microcatheter through a single clear corneal incision. Intelligently engineered with an internal reservoir delivering a controlled amount of viscoelastic fluid.
To address the trabecular meshwork as a point of resistance within the conventional outflow pathway, the OMNI Surgical System lets you perform a titratable trabeculotomy customized to meet your surgical plan.
Important Safety Information
Indications for use
The OMNI® Surgical System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example Healon® or HealonGV® from Abbott Medical Optics (AMO), Amvisc® from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery. It is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.
The OMNI® Surgical System is cleared (indicated) by FDA for the uses set forth above. While the OMNI system is not specifically cleared for transluminal canal dilation, there is support for its use (and the use of one of its parent devices, the VISCO360) in transluminal canal dilation in the literature and medical textbooks1,2,3,4, and ab interno trabeculotomy, for which it is FDA-cleared, is referred to as a MIGS procedure in the literature and medical textbooks and dictionaries.1,2,4,5,6
1. The OMNI System should not be used in cases where there is insufficient visualization of the anterior chamber. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit surgeon view.
2. Monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, appropriate management of intraocular pressure should be initiated, including medication or surgery.
Potential adverse events
Adverse events that may be reasonably associated with the use of the OMNI System in the eye include, but are not limited to, the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including, but not limited to, glaucoma surgery, and vitreous hemorrhage.
Federal (USA) law restricts this device to sale, distribution, or use by or on the order of a physician.
3000 Sand Hill Road, Building 3, Suite 105
Menlo Park, CA 94025
OMNI®is a registered trademark of Sight Sciences.
© 2019 Sight Sciences. All rights reserved.